Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Changing Donor Was Critical for the Successful Salvage Second Transplantation for Graft Failure after the First Allogeneic Stem Cell Transplantation: A Chinese Multicenter Retrospective Study

Blood (2024) 144 (Supplement 1): 2109.

https://doi.org/10.1182/blood-2024-205561

Published: 2024

Journal Articles

Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis

Yuhang Cheng, Xueyan Sun, Meijuan Huang, Lei Zhao, Jue Wang, Hanyu Wang, Wanying Liu, Shanwei Ye, Liang Huang, Gaoxiang Wang, Yang Cao

Blood (2024) 144 (Supplement 1): 1447.

https://doi.org/10.1182/blood-2024-207442

Published: 2024

Journal Articles

Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly

Meijuan Huang, Lei Zhao, Yuhang Cheng, Liang Huang, Jianfeng Zhou, Dengju Li, Jue Wang, Yang Cao

Blood (2024) 144 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2024-197968

Published: 2024

Journal Articles

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Blood (2024) 144 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2024-206408

Published: 2024

Journal Articles

Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

Jingtao Huang, Jing Zhou, Shixuan Zhang, Ruoxuan Zhang, Zengkai Pan, Luxiang Wang, Chuanhe Jiang, Jiayu Huang, Zilu Zhang, Yanmin Zhao, Yang Cao, Jianmin Wang, Xiaoxia Hu

Blood (2024) 144 (Supplement 1): 268.

https://doi.org/10.1182/blood-2024-202762

Published: 2024

Journal Articles

Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Jia Wei, Xiaoxi Zhou, Hui Luo, Yang Cao, Jiaqi Guo, Jie Zhao, Lifang Huang, Ang Zhang, Lihong Liu, Weiwei Tian, Yicheng Zhang

Blood (2024) 144 (Supplement 1): 3132.

https://doi.org/10.1182/blood-2024-205207

Published: 2024

Journal Articles

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Yuanyuan Zhang, Meijuan Huang, Tianjiao Liu, Yuhang Cheng, Dengju Li, Yang Cao, Wei Mu, Liting Chen, Li Zhu, Tongjuan Li, Liang Huang, Jia Wei, Lei Zhao, Jue Wang

Blood (2024) 144 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2024-206731

Published: 2024

Journal Articles

Establishment of a Novel Waldenström's Macroglobulinemia (WM) Cell Line Bcwm.2 with Del6q and Unique MYD88 S243N , LYN I297N , SPI1 Q227E Mutations and That Shows Robust In Vivo Engraftment in SCID NOD Mice

Shirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, Amanda Kofides, Kara M Soroko, Johany Penailillo, Alexa G Canning, Yang Cao, Guang Yang, Lian Xu, Nickolas Tsakmaklis, Maria Luisa Guerrera, Christopher J Patterson, Ruben D. Carrasco, Prafulla C. Gokhale, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Steven P. Treon

Blood (2024) 144 (Supplement 1): 5834.

https://doi.org/10.1182/blood-2024-211381

Published: 2024

Journal Articles

Impact of Febrile Neutropenia on Mobilization Efficacy in Multiple Myeloma Patients and Post-Transplant Infection Risk in Lymphoma Patients: Insights from Real-World Multicenter Data

Hu Qian, Xinwei Wang, Liping Yang, Juan Peng, Jie Zhao, Shaolong He, Jin Zhao, Jiaqi Guo, Yuekun Fang, Fankai Meng, Yang Cao, Lifang Huang, Junni Wei, Liangming Ma, Li-Ping Su, Weiwei Tian, Yicheng Zhang, Jia Wei

Blood (2024) 144 (Supplement 1): 7834.

https://doi.org/10.1182/blood-2024-205222

Published: 2024

Journal Articles

CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma

Qiuxia Yu, Daizi Gang, Jue Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Xiaoxi Zhou, Yang Cao

Blood (2023) 142 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2023-180363

Published: 2023

Journal Articles

UBC9 Deficiency Accelerates AML Progression By Downregulating PARP1 Sumoylation and Subsequently Activating the NF-ΚB Pathway

Jing Zhou, Xing Chen, Yang Cao, Liang Huang, Gaoxiang Wang

Blood (2023) 142 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2023-185601

Published: 2023

Journal Articles

MRD Positivity Was the Poor Prognostic Factor for Adverse-Risk AML Patients with Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Trohpy Study

Yang Cao, Wenxuan Huo, Yang Yang, Jiayu Huang, Yu Wang, Liang Huang, Yingjun Chang, Xiaoxia Hu, Xiaodong Mo

Blood (2023) 142 (Supplement 1): 3620.

https://doi.org/10.1182/blood-2023-185667

Published: 2023

Journal Articles

Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

Qiuxia Yu, Xiaoying Zhang, Na Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Jianfeng Zhou, Gaoxiang Wang, Yang Cao

Blood (2022) 140 (Supplement 1): 10311–10312.

https://doi.org/10.1182/blood-2022-165174

Published: 2022

Journal Articles

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Qiuxia Lv, Qiuxia Yu, Yang Cao, Jue Wang, Yicheng Zhang, Gaoxiang Wang, Zhenya Hong, Li Meng

Blood (2022) 140 (Supplement 1): 11688–11689.

https://doi.org/10.1182/blood-2022-157416

Published: 2022

Journal Articles

Be Cautious to Adopt a Second CAR T-Cell Infusion after Failure of CD19/CD22 Cocktail CAR T-Cell Therapy in Relapsed/Refractory B-NHL

Xin Yang, Gaoxiang Wang, Xiaoying Zhang, Qiuxia Yu, Yang Cao, Liang Huang

Blood (2022) 140 (Supplement 1): 4604–4605.

https://doi.org/10.1182/blood-2022-168419

Published: 2022

Journal Articles

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

JIA Wei, Min Xiao, Zekai Mao, Yang Cao, Yi Xiao, Fankai Meng, Yicheng Zhang, Jianfeng Zhou, Liang Huang

Blood (2021) 138 (Supplement 1): 94.

https://doi.org/10.1182/blood-2021-147278

Published: 2021

Journal Articles

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Blood (2021) 138 (17): 1535–1539.

https://doi.org/10.1182/blood.2021012953

Published: 2021

Includes: Supplemental data

Journal Articles

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MDPhD, Min Xiao, Zekai Mao, Na Wang, MD PhD, Chunrui Li, MDPhD, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, PhD, Yicheng Zhang, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD, Liang Huang, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138947

Published: 2020

Journal Articles

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Yang Cao, Yi Xiao, Na Wang, MD PhD, Gaoxiang Wang, MDPhD, Xiaoxi Zhou, MDPhD, Liang Huang, MD, Liting Chen, PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, Jianfeng Zhou, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-140308

Published: 2020

Journal Articles

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Wenyue Cao, Jia Wei, Na Wang, Hao Xu, Min Xiao, Lifang Huang, Yang Cao, Chunrui Li, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Dengju Li, Yichen Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang

Blood (2020) 136 (4): 516–519.

https://doi.org/10.1182/blood.2020004907

Published: 2020

Includes: Supplemental data

NARROW

Changing Donor Was Critical for the Successful Salvage Second Transplantation for Graft Failure after the First Allogeneic Stem Cell Transplantation: A Chinese Multicenter Retrospective Study

Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis

Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly

A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Establishment of a Novel Waldenström's Macroglobulinemia (WM) Cell Line Bcwm.2 with Del6q and Unique MYD88 S243N , LYN I297N , SPI1 Q227E Mutations and That Shows Robust In Vivo Engraftment in SCID NOD Mice

Impact of Febrile Neutropenia on Mobilization Efficacy in Multiple Myeloma Patients and Post-Transplant Infection Risk in Lymphoma Patients: Insights from Real-World Multicenter Data

CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma

UBC9 Deficiency Accelerates AML Progression By Downregulating PARP1 Sumoylation and Subsequently Activating the NF-ΚB Pathway

MRD Positivity Was the Poor Prognostic Factor for Adverse-Risk AML Patients with Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Trohpy Study

Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation

Be Cautious to Adopt a Second CAR T-Cell Infusion after Failure of CD19/CD22 Cocktail CAR T-Cell Therapy in Relapsed/Refractory B-NHL

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only